Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Corrigendum to 'A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours' [Eur J Cancer 104 (November 2018) 1-8].

Gazzah A, Boni V, Soria JC, Calles A, Even C, Doger B, Mahjoubi L, Bahleda R, Ould-Kaci M, Esler A, Nazabadioko S, Calvo E.

Eur J Cancer. 2019 Jul 30. pii: S0959-8049(18)31564-8. doi: 10.1016/j.ejca.2018.12.018. [Epub ahead of print] No abstract available.

PMID:
31375258
2.

Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases.

Flippot R, Biondani P, Auclin E, Xiao D, Hendriks L, Le Rhun E, Leduc C, Beau-Faller M, Gervais R, Remon J, Adam J, Planchard D, Lavaud P, Naltet C, Caramella C, Le Pechoux C, Lacroix L, Gazzah A, Mezquita L, Besse B.

J Thorac Oncol. 2019 Aug;14(8):1400-1407. doi: 10.1016/j.jtho.2019.05.007. Epub 2019 May 18.

PMID:
31108248
3.

A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours.

Mak G, Soria JC, Blagden SP, Plummer R, Fleming RA, Nebot N, Zhang J, Mazumdar J, Rogan D, Gazzah A, Rizzuto I, Greystoke A, Yan L, Tolson J, Auger KR, Arkenau HT.

Br J Cancer. 2019 May;120(10):975-981. doi: 10.1038/s41416-019-0452-3. Epub 2019 Apr 17.

4.

Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.

Hendriks LEL, Henon C, Auclin E, Mezquita L, Ferrara R, Audigier-Valette C, Mazieres J, Lefebvre C, Rabeau A, Le Moulec S, Cousin S, Duchemann B, le Pechoux C, Botticella A, Ammari S, Gazzah A, Caramella C, Adam J, Lechapt E, Planchard D, De Ruysscher D, Dingemans AM, Besse B.

J Thorac Oncol. 2019 Jul;14(7):1244-1254. doi: 10.1016/j.jtho.2019.02.009. Epub 2019 Feb 16.

PMID:
30780002
5.

Immunothérapie des glioblastomes.

Baldini C, Romano PM, Varga A, Champiat S, Dumont S, Dhermain F, Louvel G, Marabelle A, Postel-Vinay S, Angevin E, Gazzah A, Ribrag V, Bahleda R, Michot JM, Hollebecque A, Soria JC, Massard C.

Bull Cancer. 2018 Dec;105 Suppl 1:S59-S67. doi: 10.1016/S0007-4551(18)30391-6. Review. French.

PMID:
30595200
6.

Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation.

Gauci ML, Lanoy E, Champiat S, Caramella C, Ammari S, Aspeslagh S, Varga A, Baldini C, Bahleda R, Gazzah A, Michot JM, Postel-Vinay S, Angevin E, Ribrag V, Hollebecque A, Soria JC, Robert C, Massard C, Marabelle A.

Clin Cancer Res. 2019 Feb 1;25(3):946-956. doi: 10.1158/1078-0432.CCR-18-0793. Epub 2018 Oct 8.

PMID:
30297458
7.

A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours.

Gazzah A, Boni V, Soria JC, Calles A, Even C, Doger B, Mahjoubi L, Bahleda R, Ould-Kaci M, Esler A, Nazabadioko S, Calvo E.

Eur J Cancer. 2018 Nov;104:1-8. doi: 10.1016/j.ejca.2018.07.011. Epub 2018 Oct 1. Erratum in: Eur J Cancer. 2019 Jul 30;:.

PMID:
30278378
8.

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.

Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C.

JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676.

9.

Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression.

Bernard-Tessier A, Baldini C, Martin P, Champiat S, Hollebecque A, Postel-Vinay S, Varga A, Bahleda R, Gazzah A, Michot JM, Ribrag V, Armand JP, Marabelle A, Soria JC, Massard C.

Eur J Cancer. 2018 Sep;101:160-164. doi: 10.1016/j.ejca.2018.06.005. Epub 2018 Jul 30.

PMID:
30071444
10.

Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience.

Besle S, Schultz E, Hollebecque A, Varga A, Baldini C, Martin P, Postel-Vinay S, Bahleda R, Gazzah A, Michot JM, Marabelle A, Angevin E, Armand JP, Ribrag V, Soria JC, Massard C.

Eur J Cancer. 2018 Jul;98:17-22. doi: 10.1016/j.ejca.2018.04.019. Epub 2018 May 30.

PMID:
29859337
11.

Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica.

Mahjoubi L, Cecchi F, Massard C, Calabro F, Gazzah A, Bahleda R, Jamme P, Gelli M, Goere D, Lacroix L, Adam J, Heukamp L, Trenta P, Hembrough T, Soria JC, Sternberg C, Ducreux M.

Tumori. 2018 Dec;104(6):NP38-NP41. doi: 10.1177/0300891618763215. Epub 2018 Mar 21.

PMID:
29714649
12.

Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours.

Herin H, Aspeslagh S, Castanon E, Dyevre V, Marabelle A, Varga A, Postel Vinay S, Michot JM, Ribrag V, Gazzah A, Bahleda R, Mir O, Massard C, Hollebecque A, Soria JC, Baldini C.

Eur J Cancer. 2018 May;95:68-74. doi: 10.1016/j.ejca.2018.03.002. Epub 2018 Apr 7.

PMID:
29635146
13.

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.

Cabel L, Fuerea A, Lacroix L, Baldini C, Martin P, Hollebecque A, Postel-Vinay S, Varga A, Balheda R, Gazzah A, Michot JM, Marabelle A, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, Scoazec JY, Ammari S, André F, Soria JC, Massard C, Verlingue L.

Oncotarget. 2018 Jan 12;9(11):9741-9750. doi: 10.18632/oncotarget.24188. eCollection 2018 Feb 9.

14.

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

Verlingue L, Hollebecque A, Lacroix L, Postel-Vinay S, Varga A, El Dakdouki Y, Baldini C, Balheda R, Gazzah A, Michot JM, Marabelle A, Mir O, Arnedos M, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, André F, Deutsch E, Scoazec JY, Soria JC, Massard C.

Eur J Cancer. 2018 Mar;92:1-10. doi: 10.1016/j.ejca.2017.12.020. Epub 2018 Feb 3.

PMID:
29413684
15.

Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients.

Mezquita L, Charrier M, Faivre L, Dupraz L, Lueza B, Remon J, Planchard D, Bluthgen MV, Facchinetti F, Rahal A, Polo V, Gazzah A, Caramella C, Adam J, Pignon JP, Soria JC, Chaput N, Besse B.

Lung Cancer. 2017 Oct;112:10-15. doi: 10.1016/j.lungcan.2017.07.004. Epub 2017 Jul 29.

PMID:
29191581
16.

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.

Tazdait M, Mezquita L, Lahmar J, Ferrara R, Bidault F, Ammari S, Balleyguier C, Planchard D, Gazzah A, Soria JC, Marabelle A, Besse B, Caramella C.

Eur J Cancer. 2018 Jan;88:38-47. doi: 10.1016/j.ejca.2017.10.017. Epub 2017 Nov 26.

PMID:
29182990
17.

Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.

Bahleda R, Le Deley MC, Bernard A, Chaturvedi S, Hanley M, Poterie A, Gazzah A, Varga A, Touat M, Deutsch E, Massard C, Van De Velde H, Hollebecque A, Sallansonnet-Froment M, Ricard D, Taillia H, Angevin E, Ribrag V, Soria JC.

Invest New Drugs. 2018 Aug;36(4):619-628. doi: 10.1007/s10637-017-0531-3. Epub 2017 Nov 2.

PMID:
29094232
18.

Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer.

Mahjoubi L, Gazzah A, Marabelle A, Le Roy Ladurie F, Lambotte O, Caramella C, Adam J, Besse B, Soria JC.

Eur J Cancer. 2017 Nov;85:155-157. doi: 10.1016/j.ejca.2017.07.049. Epub 2017 Sep 13. No abstract available.

PMID:
28917814
19.

Are phase I trials safe for older patients?

Baldini C, Le Saux O, Helissey C, Aspeslagh S, Castanon E, Varga A, Gazzah A, Bahleda R, Mir O, Massard C, Soria JC, Hollebecque A.

J Geriatr Oncol. 2018 Mar;9(2):87-92. doi: 10.1016/j.jgo.2017.08.012. Epub 2017 Sep 8. Review.

PMID:
28890328
20.

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).

Bigot F, Castanon E, Baldini C, Hollebecque A, Carmona A, Postel-Vinay S, Angevin E, Armand JP, Ribrag V, Aspeslagh S, Varga A, Bahleda R, Menis J, Gazzah A, Michot JM, Marabelle A, Soria JC, Massard C.

Eur J Cancer. 2017 Oct;84:212-218. doi: 10.1016/j.ejca.2017.07.027. Epub 2017 Aug 18.

PMID:
28826074
21.

Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.

Angevin E, Cassier PA, Italiano A, Gonçalves A, Gazzah A, Terret C, Toulmonde M, Gravis G, Varga A, Parlavecchio C, Paci A, Poinsignon V, Soria JC, Drubay D, Hollebecque A.

Eur J Cancer. 2017 Sep;83:194-202. doi: 10.1016/j.ejca.2017.06.036. Epub 2017 Jul 24.

PMID:
28750271
22.

Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours.

Hollebecque A, Bahleda R, Faivre L, Adam J, Poinsignon V, Paci A, Gomez-Roca C, Thery JC, Le Deley MC, Varga A, Gazzah A, Ileana E, Gharib M, Angevin E, Malekzadeh K, Massard C, Soria JC, Spano JP.

Eur J Cancer. 2017 Aug;81:81-89. doi: 10.1016/j.ejca.2017.05.021. Epub 2017 Jun 12.

PMID:
28618305
23.

Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials.

Michot JM, Benajiba L, Faivre L, Baldini C, Haddag L, Bonnet C, Massard C, Bigot F, Bigenwald C, Verret B, Thomas ZAP, Varga A, Gazzah A, Hollebecque A, Ghez D, Lazarovici J, Balheda R, Jeanson A, Postel-Vinay S, Danu A, Soria JC, Paoletti X, Ribrag V.

Invest New Drugs. 2018 Feb;36(1):62-74. doi: 10.1007/s10637-017-0480-x. Epub 2017 Jun 9.

PMID:
28597151
24.

Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors.

Aspeslagh S, Shailubhai K, Bahleda R, Gazzah A, Varga A, Hollebecque A, Massard C, Spreafico A, Reni M, Soria JC.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1257-1265. doi: 10.1007/s00280-017-3303-z. Epub 2017 Apr 19.

PMID:
28424962
25.

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.

Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, Verlingue L, Ileana E, Rosellini S, Ammari S, Ngo-Camus M, Bahleda R, Gazzah A, Varga A, Postel-Vinay S, Loriot Y, Even C, Breuskin I, Auger N, Job B, De Baere T, Deschamps F, Vielh P, Scoazec JY, Lazar V, Richon C, Ribrag V, Deutsch E, Angevin E, Vassal G, Eggermont A, André F, Soria JC.

Cancer Discov. 2017 Jun;7(6):586-595. doi: 10.1158/2159-8290.CD-16-1396. Epub 2017 Apr 1.

26.

Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system.

Benajiba L, Michot JM, Baldini C, Faivre L, Varga A, Balheda R, Gazzah A, Ileana E, Postel-Vinay S, Massard C, de Botton S, Soria JC, Ribrag V.

Anticancer Drugs. 2017 Jun;28(5):540-545. doi: 10.1097/CAD.0000000000000487.

PMID:
28225458
27.

Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.

Remon J, Caramella C, Jovelet C, Lacroix L, Lawson A, Smalley S, Howarth K, Gale D, Green E, Plagnol V, Rosenfeld N, Planchard D, Bluthgen MV, Gazzah A, Pannet C, Nicotra C, Auclin E, Soria JC, Besse B.

Ann Oncol. 2017 Apr 1;28(4):784-790. doi: 10.1093/annonc/mdx017.

PMID:
28104619
28.

Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials.

Boissier E, Mir O, Hollebecque A, Izzedine H, Ederhy S, Gazzah A, Bahleda R, Massard C, Macquin-Mavier I, Tournigand C, Spano JP, Soria JC, Rousseau B.

Invest New Drugs. 2017 Feb;35(1):79-86. doi: 10.1007/s10637-016-0402-3. Epub 2016 Oct 25.

PMID:
27783256
29.

Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials.

Hollebecque A, Lanoy E, Troallen F, Soulat-Dufour L, Massard C, Bahleda R, Varga A, Gazzah A, Postel-Vinay S, Ribrag V, Deutsch E, Angevin E, Boccara F, Cohen A, Soria JC, Ederhy S.

Int J Cardiol. 2016 Jul 1;214:364-9. doi: 10.1016/j.ijcard.2016.04.010. Epub 2016 Apr 7.

PMID:
27085130
30.

A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib.

Mahjoubi L, Gazzah A, Besse B, Lacroix L, Soria JC.

Invest New Drugs. 2016 Jun;34(3):397-8. doi: 10.1007/s10637-016-0332-0. Epub 2016 Feb 18.

PMID:
26892698
31.

Immune-related adverse events with immune checkpoint blockade: a comprehensive review.

Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O.

Eur J Cancer. 2016 Feb;54:139-148. doi: 10.1016/j.ejca.2015.11.016. Epub 2016 Jan 5. Review.

PMID:
26765102
32.

Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours.

Bahleda R, Hollebecque A, Varga A, Gazzah A, Massard C, Deutsch E, Amellal N, Farace F, Ould-Kaci M, Roux F, Marzin K, Soria JC.

Br J Cancer. 2015 Nov 17;113(10):1413-20. doi: 10.1038/bjc.2015.374. Epub 2015 Oct 29.

33.

Patients aged over 75 years enrolled in Phase I clinical trials: the Gustave Roussy experience.

Helissey C, Biondani P, Roquet F, Lanoy E, Mir O, Varga A, Massard C, Gazzah A, Ribrag V, Bahleda R, Postel-Vinay S, Angevin E, Deutsch E, Soria JC, Hollebecque A.

Int J Cancer. 2016 Feb 15;138(4):875-80. doi: 10.1002/ijc.29849. Epub 2015 Oct 13.

34.

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.

Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, Calvo E, Moreno V, Adamo B, Gazzah A, Zhong B, Platero SJ, Smit JW, Stuyckens K, Chatterjee-Kishore M, Rodon J, Peddareddigari V, Luo FR, Soria JC.

J Clin Oncol. 2015 Oct 20;33(30):3401-8. doi: 10.1200/JCO.2014.60.7341. Epub 2015 Aug 31.

PMID:
26324363
35.

Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non-Small Cell Lung Cancer Patient.

Remon J, Gazzah A, Besse B, Soria JC.

J Thorac Oncol. 2015 Aug;10(8):e72-3. doi: 10.1097/JTO.0000000000000561. No abstract available.

36.

Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy.

Kossai M, Duchemann B, Boutros C, Caramella C, Hollebecque A, Angevin E, Gazzah A, Bahleda R, Ileana E, Massard C, Vielh P, Soria JC, Besse B.

Lung Cancer. 2015 Sep;89(3):306-10. doi: 10.1016/j.lungcan.2015.06.014. Epub 2015 Jun 22.

PMID:
26160757
37.

A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma.

Hollebecque A, Deutsch E, Massard C, Gomez-Roca C, Bahleda R, Ribrag V, Bourgier C, Lazar V, Lacroix L, Gazzah A, Varga A, de Baere T, Beier F, Kroesser S, Trang K, Zenke FT, Klevesath M, Soria JC.

Invest New Drugs. 2013 Dec;31(6):1530-8.

PMID:
24077982
38.

Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?

Gazzah A, Gonzales DB, Levy A, Bahleda R, Ducreux M, Lacroix L, Soria JC.

Onco Targets Ther. 2013;6:95-7. doi: 10.2147/OTT.S38520. Epub 2013 Feb 20.

39.

First case report of intrathecal panitumumab for treatment of meningeal carcinomatousis in an EGFR mutant lung adenocarcinoma patient.

Hollebecque A, Levy A, Broutin S, Lemare F, Gazzah A, Desmaris R, Chenailler C, Elbaum M, Besse B, Paci A, Soria JC.

Lung Cancer. 2013 Apr;80(1):113-4. doi: 10.1016/j.lungcan.2012.12.016. Epub 2013 Jan 23. No abstract available.

PMID:
23352031
40.

Identification of proteins related to early changes observed in Human hepatocellular carcinoma cells after treatment with the mycotoxin Zearalenone.

Gazzah AC, Camoin L, Abid S, Bouaziz C, Ladjimi M, Bacha H.

Exp Toxicol Pathol. 2013 Sep;65(6):809-16. doi: 10.1016/j.etp.2012.11.007. Epub 2013 Jan 3.

PMID:
23290424
41.

Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: a prospective study in a Phase I clinical trial unit of predominantly targeted anticancer drugs.

Rouanne M, Massard C, Hollebecque A, Rousseau V, Varga A, Gazzah A, Neuzillet Y, Lebret T, Soria JC.

Eur J Cancer. 2013 Jan;49(2):431-8. doi: 10.1016/j.ejca.2012.08.008. Epub 2012 Sep 6.

PMID:
22959468
42.

[Focus on targeting the Ras-MAPK pathway: the Mek inhibitors].

Baldini C, Duchemann B, Hollebecque A, Routier É, Varga A, Gazzah A, Bahleda R, Besse B, Soria JC, Massard C.

Bull Cancer. 2012 Sep;99(9):865-74. doi: 10.1684/bdc.2012.1632. Review. French.

43.

iTRAQ: a method to elucidate cellular responses to mycotoxin zearalenone.

Gazzah AC, Camoin L, Abid S, Bacha H, Ladjimi M.

J Appl Toxicol. 2013 Jul;33(7):566-75. doi: 10.1002/jat.1766. Epub 2012 Jun 25.

PMID:
22729511
44.

Sequential events of apoptosis induced by zearalenone in cultured hepatocarcinoma cells.

Gazzah AC, El Golli Bennour E, Bouaziz C, Abid S, Ladjimi M, Bacha H.

Mycotoxin Res. 2010 Aug;26(3):187-97. doi: 10.1007/s12550-010-0053-8. Epub 2010 May 20.

PMID:
23605383
45.

[Breast cancer in the elderly].

Gutierrez M, Ben Abid F, Ousbane A, Gazzah A, Debled M, Girre V, Brain EG.

Bull Cancer. 2008 May 28;95 FMC Onco:F51-6. doi: 10.1684/bdc.2007.0562. French.

PMID:
18511367

Supplemental Content

Loading ...
Support Center